Scientific Research News

BELLINGHAM, Wash.--(BUSINESS WIRE)--SPIE, the international society for optics and photonics, brought the global optics and photonics community to San Francisco, California, for another successful and enlivening Photonics West. With more than 23,000 registrants, the annual conference and exhibition connected attendees from 40 countries, showcasing the transnational and collaborative spirit of the interdisciplinary industry. The dynamic event ran from 17 to 22 January, with 4,200 technical prese...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences: BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Format: One-on-one meetings When: Tuesday, February 10, 2026 Location...

BALTIMORE--(BUSINESS WIRE)--Medifast (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney...

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...

NEW YORK--(BUSINESS WIRE)--Churchill Capital Corp X (“Churchill X”), a special purpose acquisition company, today announced Churchill X’s intent to transfer the listing of its Class A ordinary shares, par value $0.0001 per share (the “Class A Ordinary Shares”) and public warrants (the “CCX Warrants”) (each, the Common Stock and Warrants following transactions contemplated by the Business Combination, as defined below), from the Nasdaq Stock Market LLC (“Nasdaq”) to the New York Stock Exchange (...

TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, a leader in AI-powered multimodal spatial biology, today announced its contribution to a collaborative international study published in Nature Communications that explores how spatial organization and metabolic characteristics of tumor cells are associated with response and resistance to immunotherapy in non-small cell lung cancer (NSCLC). The study, led by academic researchers at The University of Queensland and Yale School of Medicine, applied multi...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with s...

DENVER--(BUSINESS WIRE)--Xcimer Energy announced today that its researchers and collaborators have removed a major scientific bottleneck to commercializing laser fusion energy by experimentally validating a long-overlooked physics regime which enables next-generation fusion lasers. In a peer-reviewed paper published in APL Photonics, researchers from Xcimer, the University of Illinois, and the University of Alberta reported the first absolute, high-resolution measurements of Stimulated Brilloui...

AUSTIN, Texas--(BUSINESS WIRE)--VMD Sciences, the leader in global veterinary pharmaceutical access services, announced the successful, compliant importation by a U.S. licensed veterinarian of an advanced cancer therapy approved in Europe. The specialized tyrosine kinase inhibitor unavailable in the U.S. was for the treatment of Jetta, an 8-year-old mixed-breed dog battling metastatic mast cell cancer. Through their Managed Access Program (MAP), VMD Sciences supported Dr. Seth Glasser, DVM, Dip...

MELBOURNE, Australia--(BUSINESS WIRE)--Imagion Biosystems, Ltd. announced that the company has lodged an IND application with the FDA for its MagSense® targeted imaging agent....